amantadine sold brand name gocovri among others medication used treat dyskinesia associated parkinsonism influenza caused type influenzavirus though use latter longer recommended due widespread drug acts nicotinic antagonist dopamine agonist noncompetitive nmda antiviral mechanism action antagonism influenzavirus proton channel prevents endosomal escape ie release viral genetic material host amantadine first used treatment influenza antiviral properties initially reported amantadine received approval prophylaxis influenza virus food drug administration fda approved amantadine use treatment parkinsons disease extended release formulation approved use treatment levodopainduced amantadine mild side effect profile common neurological side effects include drowsiness light headedness dizziness due effects central nervous system caution combined additional cns stimulants anticholinergic drugs amantadine contraindicated persons end stage kidney disease given drug cleared also taken caution enlarged prostates glaucoma due anticholinergic amantadine brand names gocovri symadine organic compound consists adamantane backbone amino group substituted one four tertiary rimantadine closely related adamantane derivative similar biological target proton channel influenza mechanism antiparkinsonian effect poorly amantadine weak antagonist nmdatype glutamate receptor increases dopamine release blocks dopamine amantadine probably inhibit monoamine oxidase mao moreover drug many effects brain including release dopamine norepinephrine nerve endings appears anticholinergic specifically nicotinic receptors like similar pharmaceutical discovered amantadine memantine bind act agonists receptor ki μm μm respectively activation receptor involved dopaminergic effects amantadine therapeutically relevant speculation findings may also extend adamantanes adapromine rimantadine bromantane could explain psychostimulantlike effects family compounds seem evidence available regarding needed mechanisms amantadines antiviral antiparkinsonian effects amantadine targets influenza ion channel protein proteins function allow intracellular virus replicate also functions proton channel hydrogen ions cross vesicle exocytose newly formed viral proteins extracellular space viral shedding blocking channel virus unable replicate impaired replication protein synthesis amantadine rimantadine function mechanistically identical fashion entering barrel tetrameric channel blocking pore proton resistance drug class consequence mutations porelining amino acid residues channel preventing amantadine rimantadine binding inhibiting channel usual amantadine well absorbed orally onset action usually within hours used parkinsonian syndromes including dyskinesia plasma concentrations amantadine increase greater risk halflife elimination averages eight days patients endstage kidney disease amantadine minimally removed amantadine metabolized small extent acetylation mainly excreted unchanged urine kidney amantadine used treat parkinsons diseaserelated dyskinesia druginduced parkinsonism amantadine may used alone combination another antiparkinsons anticholinergic specific symptoms targeted amantadine therapy dyskinesia extended release amantadine formulation commonly used treat dyskinesias people receiving levodopa therapy parkinsons cochrane review concluded insufficient evidence prove safety efficacy amantadine treat world health organization reported amantadine effective standalone parkinsonian therapy recommended could used combination therapy amantadine recommended treatment prophylaxis influenza united amantadine effect preventing treating influenza b us centers disease control prevention found seasonal pandemic flu samples resistant adamantanes amantadine rimantadine flu us centers disease control prevention cdc guidelines recommend neuraminidase inhibitors influenza treatment prophylaxismedical citation needed cdc recommends amantadine rimantadine treat influenza similarly world health organization virology report showed tested influenza viruses resistant guidelines recommend use inhibitors influenza amedical citation needed continued high rate resistance observed laboratory testing influenza reduced priority resistance testingmedical citation needed cochrane review find evidence efficacy safety amantadine used prevention treatment influenza extended release formulation used treat levodopainduced dyskinesia patients parkinsons recommends use amantadine combination therapy reduce levodopa side cochrane literature review concluded overall evidence supporting use amantadine treating fatigue patients followup cochrane review stated may amantadineinduced improvement fatigue people despite multiple control trials also demonstrated improvements subjective objective ratings fatigue final conclusion regarding consensus guidelines german multiple sclerosis society gmss state amantadine produces moderate improvement subjective fatigue problem solving memory concentration thus gmss guidelines recommended use amantadine msrelated uk nice recommends considering amantadine ms disorders consciousness doc include coma vegetative state vs minimally conscious state mcs amantadine shown increase rate emergence mcs defined consistent demonstration interactive communication functional objective use traumatic brain injury patients intensive care unit amantadine also shown various randomized control trials increase rate functional recovery arousal particularly time period immediately following also reports significantly improved consciousness patients treated nontraumatic cases doc case subarachnoid hemorrhage cerebral hemorrhage hypoxic american academy neurology aan updated treatment guidelines use amantadine patients prolonged doc recommending use amantadine mg bid adults doc weeks post injury support early functional recovery reduce various studies amantadine memantine shown accelerate rate recovery brain timelimited window following brain injury characterized neuroplasticity capacity neurons brain adapt compensate injury thus physiatrists often start patients amantadine soon impairments recognized also case reports showing improved functional recovery amantadine treatment occurring years initial brain insufficient evidence determine functional gains result effects dopamine norepinephrine pathways patients may benefit direct dopamine stimulation amantadine others may benefit stimulants act norepinephrine pathway unclear treatment amantadine improves longterm outcomes simply accelerates nonetheless amantadineinduced acceleration recovery reduces burden disability lessens health care costs minimizes psychosocial stressors patientscitation needed randomized clinical trial showed similar improvements adhd symptoms children treated amantadine treated methylphenidate less frequent side retrospective study showed amantadine may serve effective adjunct stimulants symptoms appears safer alternative second thirdgeneration amantadine generally well tolerated mild sideeffect side effects include drowsiness especially driving lightheadedness falls patients amantadine avoid combination central nervous system cns depressing agents alcohol excessive alcohol usage may increase potential cns effects dizziness confusion light rare severe adverse effects include neuroleptic malignant syndrome depression convulsions psychosis suicidal also associated disinhibited actions gambling sexual activity spending addictions diminished control amantadine may cause orthostatic hypotension syncope peripheral amantadine also associated dry mouth rare cases skin rashes syndrome livedo reticularis also reported patients treated amantadine inhibits kidneys activetransport removal transfer creatinine blood urine normally occurs proximal tubules nephrons activetransport removal mechanism accounts fifteen percent creatinine clearance therefore amantadine may increase serum creatinine concentrations fifteen percent normal levels give false impression mild kidney disease patients whose kidneys actually undamaged kidney function often assessed measuring concentration creatinine blood also patient kidney disease amantadine may cause appear much fifteen percent worse actually amantadine food drug administration category c pregnancy teratogenic effects observed humans case reports animal reproduction studies amantadine may also present breast milk negatively alter breast milk production excretion decision breastfeed amantadine therapy consider risk infant exposure benefits breastfeeding benefits drug amantadine may affect central nervous system due dopaminergic anticholinergic properties mechanisms action fully known cns effects caution required prescribing additional cns stimulants anticholinergic thus concurrent use alcohol amantadine recommended due enhanced cns depressant addition antidopaminergic drugs metoclopramide typical antipsychotics interactions likely related opposing dopaminergic mechanisms action inhibits amantadines antiparkinson effectsmedical citation needed amantadine contraindicated persons end stage kidney drug renally amantadine may anticholinergic side effects thus patients enlarged prostate glaucoma use live attenuated vaccines contraindicated taking possible amantadine inhibit viral replication reduce efficacy administered vaccines us food drug administration recommends avoiding amantadine two weeks prior vaccine administration hours antiviral properties first reported university illinois hospital chicago amantadine trial study volunteer college students exposed viral challenge group received amantadine milligrams hours viral challenge less asia influenza infections placebo amantadine received approval treatment influenza virus adults first used west germany amantadine approved us food drug administration october prophylactic agent asian influenza received approval prophylactic use influenza influenza epidemic first amantadineresistance influenza viruses reported frequency amantadine resistance among influenza viruses low resistance frequency increased year later resistance increase significantly china south korea united states respectively strains amantadineresistant majority amantadineresistant isolates found contain mutation transmembrane domain confers resistance currently adamantane resistance high among circulating influenza viruses thus longer recommended treatment influenza incidental finding prompted investigations amantadines effectiveness treating symptoms parkinsons woman parkinsons disease prescribed amantadine treat influenza infection reported cogwheel rigidity tremors improved also reported symptoms worsened finished course published case report initially corroborated instances medical literature manufacturer data team researchers looked group ten patients parkinsons disease gave amantadine seven ten patients showed improvement convincing evidence need clinical trial included patients parkinsons disease experienced subjective objective reduction symptoms maximum daily dose additional studies followed patients greater lengths time different combinations neurological found safe drug could used long periods time side effects monotherapy combination ldopa anticholinergic april us food drug administration approved amantadine use treatment parkinsons us food drug administration approved use amantadine extended release formulation treatment dyskinesia adverse effect levodopa people parkinsons chinese poultry farmers reported used amantadine protect birds avian western countries according international livestock regulations amantadine approved use humans chickens china received estimated billion doses avian flu strains china southeast asia resistant amantadine although strains circulating elsewhere still seem sensitive amantadineresistant strains virus spread drugs choice avian flu outbreak probably restricted neuraminidase inhibitors oseltamivir zanamivir block action viral neuraminidase enzyme surface influenza virus however increasing incidence oseltamivir resistance circulating influenza strains eg highlighting need new antiinfluenza september us food drug administration announced recall dingo chip twists chicken middle dog treats product potential contaminated httpsenwikipediaorgwikiamantadine